摘要
目的对原发性肝细胞癌(HCC)患者血清中4种抗肿瘤相关抗原(TAA)抗体进行检测,探讨其对HCC的临床诊断价值。方法利用酶联免疫吸附试验(ELISA)对67例HCC患者血清和30名正常人血清中4种抗TAA(P53、P62、C-myc和Koc)抗体进行联合检测,利用电化学发光免疫分析技术(ECLIA)对血清中甲胎蛋白(AFP)进行检测,分析其敏感性和特异性。结果每种抗TAA抗体检测结果单独判断时,敏感性都偏低,但进行不同组合后,随着种类的增多,诊断的敏感性随之增加,4种抗TAA抗体联合检测的敏感性达到了82.1%,明显高于AFP的敏感性(68.7%),特异性达到了86.7%,阳性预测值93.2%,阴性预测值68.4%。结论利用4种抗TAA抗体联合检测能够提高HCC的诊断质量,降低漏诊率,为HCC患者临床早期诊断和高危人群筛查,以及AFP阴性的HCC患者补充测定提供了一种新方法。
Objective To investigate the diagnostic value of the serum antibodies to four tumor-associated antigens （TAA） P53,P62,C-myc and Koc for hepatocellular carcinoma（HCC）. Methods The antibodies to P53,P62,C-mye and Koc in sera from 67 patients with HCC and 30 healthy human subjects were detected by enzyme-linked immunosor- bent assay（ELISA）. Electrochemiluminescence immunoassay（ECLIA） was used to measure the serum alpha fetoprotein （AFP）. Results Individual anti-TAA assay showed relatively low positive rate for HCC. However, the sensitivity of combined assay of four anti-TAAs increased to 82.1% , higher than that of AFP（68.7% ）. The specificity, positive and negative values of combined assay were 86.7% ,93.2% and 68.4% respectively. Conclusions The sensitivity and effectiveness on HCC can be increased greatly with combined determination of anti-TAAs. A new diagnostic approach could be provided for population at high risk in HCC and especially for patients with negative AFP.
出处
《检验医学》
CAS
北大核心
2008年第3期286-289,共4页
Laboratory Medicine
关键词
肝细胞癌
诊断
肿瘤相关抗原
抗体
免疫测定
Hepatocellular carcinoma
Diagnosis
Tumor-associated antigen
Antibody
Immunoassay
